Physician profile
Lindsey M Zubritsky
NPI 1740600329
$349,268.75
in general payments reported to CMS, 2019-2025
41 companies · $88K in 2025
The $88K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $2,229 · 2021: $39K · 2022: $45K · 2023: $61K · 2024: $113K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $256K · Food and Beverage: $3,844 · Travel and Lodging: $2,011 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $256,016.68 |
| Food and Beverage | $3,844.37 |
| Travel and Lodging | $2,011.41 |
| Education | $144.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $339,298.67 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Abbvie INC. | $2,671.52 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Allergan, INC. | $1,120.00 | 2022 | |
| Janssen Biotech, INC. | $773.76 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $549.86 | 2019-2025 | |
| Lilly USA, LLC | $430.30 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $407.74 | 2019-2025 | |
| Genzyme Corporation | $364.67 | 2021-2025 | |
| Incyte Corporation | $356.36 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $346.01 | 2019-2025 | Winlevi, Absorica Ld, Blu-U |
| Organogenesis INC. | $302.98 | 2023-2025 | Puraply, Cygnus Dual, Apligraf |
| Leo Pharma INC. | $271.57 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $238.48 | 2019-2024 | Jublia, Cabtreo |
| Amgen INC. | $228.13 | 2019-2025 | Otezla |
| Ucb, INC. | $215.44 | 2019-2025 | Bimzelx |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Zubritsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.